Page 49 - Read Online

expressing elevated levels of miR-21 are chemoresistant mammalian mRNAs are conserved targets of microRNAs.
to gemcitabine and reduce the effi ciency of apoptosis Genome Res 2009;19:92-105.
induction. [148,149] miRNAs can be targeted. For example, 4. Ambros V. The functions of animal microRNAs. Nature
inhibition of mir-21 by its antagonist led to the cessation 2004;431:350-5.
of tumor growth and induction of apoptosis in vitro 5. Calin GA, Croce CM. MicroRNA signatures in human
cancers. Nat Rev Cancer 2006;6:857-66.
and in vivo (animal experimental model). [150] Another 6. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M,
therapeutic option comes from a possibility-of-function Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J,
recovery of miR-34a, a potent pro-apoptotic component Shingara J, Chin L, Brown D, Slack FJ. The let-7 microRNA
involved in p53-mediated apoptosis. As shown by Ji represses cell proliferation pathways in human cells. Cancer
et al., [151] restoration of miR-34a may substitute the Res 2007;67:7713-22.
function of inactivated TP53 gene. It has been shown 7. Kent OA, Mendell JT. A small piece in the cancer puzzle:
that miR-10a promotes the metastatic behavior of MicroRNAs as tumor suppressors and oncogenes. Oncogene
the pancreatic cancer (PC) and that its expression is 2006;25:6188-96.
regulated by retinoids. [152] The use of retinoic acid 8. Fassan M, Croce CM, Rugge M. miRNAs in precancerous
lesions of the gastrointestinal tract. World J Gastroenterol
receptor antagonists inhibit miR-10a expression and 2011;17:5231-9.
stop metastasis of PDAC cells. [152] In contrast, miR-146a 9. Song B, Ju J. Impact of miRNAs in gastrointestinal cancer
suppresses invasion of PC cells. However, its expression diagnosis and prognosis. Expert Rev Mol Med 2010;12:e33.
is lowered in PC compared to normal pancreatic tissue. 10. Boni V, Bandres E, Zarate R, Colucci G, Maiello E,
Finally, use of non-toxic natural compounds which Garcia-Foncillas J. MicroRNAs as a new potential
increase expression of miR-146a is also considered to therapeutic opportunity in gastrointestinal cancer. Oncology
be a promising approach to block both invasion and 2009;77 Suppl 1:75-89.
metastases. [153] 11. Vicentini C, Fassan M, D’Angelo E, Corbo V, Silvestris N,
Nuovo GJ, Scarpa A. Clinical application of microRNA
testing in neuroendocrine tumors of the gastrointestinal tract.
Perspective Molecules 2014;19:2458-68.
Many miRNAs can be used in the diagnosis of cancer, 12. Macha MA, Seshacharyulu P, Krishn SR, Pai P, Rachagani S,
in determining the patient prognosis or as therapeutic Jain M, Batra SK. MicroRNAs (miRNAs) as biomarker(s) for
prognosis and diagnosis of gastrointestinal (GI) cancers. Curr
targets. We must develop more stringent protocols for Pharm Des 2014;20:5287-97.
collecting and analyzing samples (to avoid variations 13. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,
in sample processing or histologic characterization) and 2002. CA Cancer J Clin 2005;55:74-108.
to validate each fi nding in large independent cohorts. 14. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med
This approach will lead to the selection of the best 2003;349:2241-52.
candidate miRNAs for further study, the development of 15. He B, Yin B, Wang B, Xia Z, Chen C, Tang J. MicroRNAs in
highly reproducible results, and reduction in inter-study esophageal cancer (review). Mol Med Rep 2012;6:459-65.
discrepancies. New miRNAs are continuously being 16. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B,
discovered, and profi ling technologies are rapidly Meng X, Ma X, Luo M, Shao K, Li N, Qiu B, Mitchelson K,
Cheng J, He J. Distinctive microRNA profi les relating to
changing. Thus, creating a standardization process for patient survival in esophageal squamous cell carcinoma.
integrating data will be challenging. Development of Cancer Res 2008;68:26-33.
effective in vivo delivery systems is also required if 17. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ,
miRNAs are to be used as therapeutics. Wu M, Swanson SJ, Godfrey TE, Litle VR. MicroRNA
expression profi les of esophageal cancer. J Thorac Cardiovasc
Although many additional studies must be performed, Surg 2008;135:255-60.
miRNAs appear to have many useful clinical applications 18. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A,
for patients with GI cancers and other GI disorders. The Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D,
GI community should look forward to these studies with Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N,
great anticipation. Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM,
Harris CC. MicroRNA expression in squamous cell carcinoma
Financial support and sponsorship and adenocarcinoma of the esophagus: Associations with
survival. Clin Cancer Res 2009;15:6192-200.
Nil. 19. Kan T, Meltzer SJ. MicroRNAs in Barrett’s esophagus
Confl icts of interest and esophageal adenocarcinoma. Curr Opin Pharmacol
2009;9:727-32.
There are no confl icts of interest. 20. Maru DM, Singh RR, Hannah C, Albarracin CT,
Li YX, Abraham R, Romans AM, Yao H, Luthra MG,
References Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A,
Luthra R. MicroRNA-196a is a potential marker of progression
1. Marusawa H, Jenkins BJ. Infl ammation and gastrointestinal during Barrett’s metaplasia-dysplasia-invasive adenocarcinoma
cancer: An overview. Cancer Lett 2014;345:153-6. sequence in esophagus. Am J Pathol 2009;174:1940-8.
2. Gartel AL, Kandel ES. miRNAs: Little known mediators of 21. Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A,
oncogenesis. Semin Cancer Biol 2008;18:103-10. Katada T, Harata K, Tanaka T, Fujii Y. Expression profi ling of
3. Friedman RC, Farh KK, Burge CB, Bartel DP. Most micro-RNAs in human esophageal squamous cell carcinoma

150 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦